Navigation Links
Two-Day Dialysis Interval Could Pose Danger: Study
Date:9/22/2011

to be seriously considered," he said.

Foley also emphasized that studies like this that draw conclusions from associations "are shaky foundations" upon which to build new treatment guidelines. He said the next step should be a trial in which patients are randomly assigned to different dialysis schedules and their outcomes compared.

Zand said concerned patients might want to explore other dialysis options with their physicians, including daily home peritoneal dialysis or night-time outpatient hemodialysis, which could add additional blood-cleansing hours. He said they can also discuss taking extra steps to reduce the risk of complications on the two-day stretches between dialysis stints by minimizing fluid intake, salty foods and high-potassium foods, such as avocados and bananas.

More information

Find out more about kidney dialysis at the U.S. National Kidney Foundation.

SOURCES: Robert Foley, M.B., deputy director, U.S. Renal Data System Coordinating Center, Minneapolis; Martin Zand, M.D., Ph.D., professor, medicine, division of nephrology, University of Rochester Medical Center, Rochester, N.Y.; Sept. 22, 2011, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Dialysis Patients Unprepared for Disasters, Study Contends
2. Acne-treating antibiotic cuts catheter infections in dialysis patients
3. Younger Blacks Fare Worse on Dialysis, Study Finds
4. Blood Pressure Drop During Dialysis May Raise Clot Risk
5. Low blood pressure during dialysis increases risk of clots, according to Stanford-led study
6. HbA1C test for glucose monitoring poorly predictive in dialysis patients
7. Many Dialysis Patients Short on Health Literacy
8. Higher Death Rates Seen in Central Line Dialysis Patients: Study
9. Home Dialysis for Kidney Patients May Ease Restless Legs Syndrome
10. Portable, less costly peritoneal dialysis shows no additional catheter risk factors
11. Many Dialysis Patients at Risk for High Radiation Exposure
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Two-Day Dialysis Interval Could Pose Danger: Study
(Date:8/29/2014)... Astoria, New York, (PRWEB) August 29, 2014 ... a degenerative condition that damages the motor neurons in the ... and more of the nerve cells controlling movement are harmed, ... functions. Eventually this leads to death. , ALS is ... and 70, and as many as 30,000 Americans have the ...
(Date:8/29/2014)... Top10BestSEOHosting.com today compares many professional ... announces that Bluehost ( http://www.bluehost.com/track/seohosts ), Arvixe, and ... for webmasters who want to buy high quality ... at affordable rates. , Bluehost is also a ... its features is that Bluehost provides quality hosting ...
(Date:8/29/2014)... CA (PRWEB) August 29, 2014 According ... a lawsuit against Pfizer Inc., Greenstone LLC and Pfizer ... with congenital birth defects as a result of ... defect lawsuit was filed in St. Clair County Circuit ... to the lawsuit, the defendant companies allegedly concealed the ...
(Date:8/29/2014)... Visiting Nurse Association of Northern New ... delivering comfort and companionship to terminally-ill patients and their ... continues to grow and their needs expand, the VNA ... The next Hospice Training Program will be offered on ... P.M. at VNA’s headquarters, 175 South Street in Morristown. ...
(Date:8/29/2014)... The Winscribe Board of Directors today announced the ... from 1st September 2014. Allen previously held the position ... time of growth, there is no better person to ... Founder and Chairman of the Board. “Allen is a ... management experience gained in New Zealand, Europe and the ...
Breaking Medicine News(10 mins):Health News:Charity Event to Raise Awareness and Donations for the ALS Foundation 2Health News:Top10BestSEOHosting.com: Bluehost, Arvixe, and Hostgator Are the Best Windows Web Hosting from the USA in 2014 2Health News:The Law Office of Melinda J. Helbock A.P.C. Comments on Zoloft Birth Defect Lawsuit 2Health News:VNA Offers Rewarding Hospice Volunteer Opportunity 2Health News:VNA Offers Rewarding Hospice Volunteer Opportunity 3Health News:Winscribe Names Greg Allen as CEO 2
... Blue Cross and Blue Shield of Georgia (BCBSGA) ... reached agreement on a three-year contract, effective August ... members can continue to access Piedmont Healthcare as ... physicians, Piedmont Hospital in Atlanta, Piedmont Fayette Hospital ...
... North America,s largest annual interdisciplinary academic conference kicks off in ... Carleton University to present and debate research from across the ... will be held this Friday at 10:30 a.m. in the ... of what to expect. , Nathalie Des Rosiers, president of ...
... By combining the expertise of its ... (BEZ.L) has developed enhanced management liability coverage ... of healthcare organizations, including hospitals, long term ... is an adaptation of Beazley,s successful BeazleyOne ...
... calls to consider reducing the legal drinking age, a new University of ... births among young people. , ... Athens, Ga. (Vocus) May 21, 2009 ... new University of Georgia study finds that lower drinking ages ...
... May 21 For the second year in a ... to donate blood through the Red Cross by joining ... Red Cross Racing is a program designed to increase ... they donate. Participants of this program can get points for ...
... shows droplets rubbed into skin prevented infections , , THURSDAY, ... rubbed into the skin appear to protect against ear ... , If this approach proves effective in humans, it ... infections, the researchers noted. , Three groups of chinchillas ...
Cached Medicine News:Health News:Blue Cross and Blue Shield of Georgia and Piedmont Healthcare Announce Contract Renewal 2Health News:Thousands of Canada's best minds converge at Congress 2009 2Health News:Beazley's New Management Liability Coverage is Tailored to Unique Needs of Healthcare Organizations 2Health News:Beazley's New Management Liability Coverage is Tailored to Unique Needs of Healthcare Organizations 3Health News:Study: Lower Legal Drinking Age Increases Poor Birth Outcomes 2Health News:Study: Lower Legal Drinking Age Increases Poor Birth Outcomes 3Health News:NASCAR Fans Boost Blood Donations; The American Red Cross Joins 3M and Greg Biffle to Kick off Season Two 2Health News:NASCAR Fans Boost Blood Donations; The American Red Cross Joins 3M and Greg Biffle to Kick off Season Two 3Health News:Pediatric Ear Infection Vaccine Shows Promise 2
(Date:8/28/2014)... NEW YORK , Aug. 28, ... a new market research report is ... Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets ... Target High Unmet Need in Newly ... http://www.reportlinker.com/p02343492/Glioblastoma-Multiforme-Therapeutics-in-Asia-Pacific-Markets-to-2020---Novel-Therapeutic-Approaches-Target-High-Unmet-Need-in-Newly-Diagnosed-and-Recurrent-GBM.html ...
(Date:8/28/2014)... DIEGO , Aug. 28, 2014 Telik, ... development company that merged with MabVax Therapeutics, Inc. ... made significant progress related to the development of ... antibody was recovered using the Company,s internally developed ... the potential for multiple antibody based therapeutic and ...
(Date:8/28/2014)... Calif. , Aug. 28, 2014 Amgen ... of a Biologics License Application (BLA) to the U.S. ... for the treatment of high cholesterol. Evolocumab is an ... subtilisin/kexin type 9 (PCSK9), a protein that reduces the ... "bad" cholesterol, from the blood. 1 ­ ...
Breaking Medicine Technology:Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 2Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 6Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 7Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 8Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 9Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 2Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 3Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 4Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 2Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 3Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 4Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 5Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 6Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 7Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 8Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 9
... A surgeon at the St. Francis Heart Center ... to rebuild their own cardiovascular tissue. , , (Logo: ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20090708/DE43062LOGO-b ) ... Extracellular Matrix (ECM)(TM) to modify and repair cardiac structures, allowing ...
... Calif., July 7 Amgen (Nasdaq: AMGN ... trial evaluating denosumab versus Zometa(R) (zoledronic acid) in the ... breast cancer met its primary and secondary endpoints and ... demonstrated for both delaying the time to the first ...
Cached Medicine Technology:St. Francis Surgeon Uses Tissue Regeneration Technology to Rebuild Patients' Heart Structures 2St. Francis Surgeon Uses Tissue Regeneration Technology to Rebuild Patients' Heart Structures 3Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 2Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 3Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 4Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 5Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 6Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 7Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 8
The Medtronic CardioRhythm Marinr Catheter is intended for use in diagnostic electrophysiologic procedures. These catheters are designed for recording intracardiac electrograms and temporary pacing a...
... designed for use with our CARTO EP ... catheter houses a Biosense Webster sensor at ... time, exact location points from within the ... The NAVI-STAR electro-anatomical navigation catheter is used ...
... Tricuspid Mapping. Biosense Webster offers a complete ... in the atrium. The HALO XP 20-pole ... and mapping around the tricuspid annulus. The ... distal tip (on P15-FS/0 permit pacing in ...
... Webster is the source for a complete ... left-sided mapping - all with the quality, ... expect from the leader in catheter technology. ... specifically designed and constructed to help minimize ...
Medicine Products: